A Paracetamol Warning, Then a Review That Better Represented the Evidence
A couple of months after the US Food and Drug Administration announced it would add a warning label to the painkiller acetaminophen (paracetamol), claiming that taking the drug during pregnancy increased a child's risk of autism, researchers published a major review that better represented the full body of knowledge. Its conclusion: "Existing evidence does not clearly link maternal paracetamol use during pregnancy with autism or ADHD in offspring." The writer who reported on the announcement argues the FDA and its parent health department cherry-picked a few studies and downplayed more robust findings. Put the two documents side by side and the difference is structural: one claim built from a selected handful of papers, one attempt to weigh everything that existed.
AI-generated discussion · Different perspectives
The transferable lesson is not that some particular paper lied. It is the report-in-isolation problem, which the writer names from experience as a science journalist: each study gets published as its own headline, weighed against nothing else we know, and a reader has no way to see the pile it is actually sitting on.
Read the review's wording closely, though. "Does not clearly link" is not a clean bill of health; it is a statement about what the collected evidence shows, which is a narrower thing than an all-clear. And the cost the writer identifies is concrete: by the time the synthesis landed, countless women had been needlessly scared about a painkiller widely considered one of the safest to take during pregnancy. Getting the synthesis later is not the same as getting it before the fear spread.